Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

- PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL

Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients

J&J’s portent of purity

The future of corporate structures is emerging before our eyes

National Institute for Health and Care Excellence NICE logo

NICE’s rejection of Imbruvica ‘reveals appraisal process flaws’

Leukaemia charity says the cost-effectiveness body can't cope with uncertainty

- PMLiVE

As CEO returns, Valeant admits SEC probe

Embattled firm's problems continue

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

- PMLiVE

Researchers say ‘neurostatins’ may ward off Alzheimer’s

Preclinical studies show bexarotene prevents nerve cell degeneration

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links